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share it. The smoking prevalence in our region was 20% in
2009–2010 [3]. This was not different to that observed in our
HCC cohort in the years 2009–2010 (20–21%), although this too
had fallen across the decade. Of relevance, the recent ‘Integrated
Health Survey’ reported by Public Health England [4] revealed
that smoking was much less common (11–12%) in those over
the age of 65 years – an age more in keeping with the age of
our cohort. The decline with age was attributed both to successful
quitting and death. The prevalence of smoking in our entire
cohort (26%, as summarised in Table 1) and in 2010 (20%) was
clearly higher than this. Table 1 presents data by etiology, with
additional signiﬁcant differences observed (p = 0.029, v2).
Current smoking was particularly high in cases with HBV related
HCC (46%), as well as being higher in those individuals without
underlying chronic liver disease (31%). Notably, there was no
increase in those with NAFLD related HCC (11%). Similarly, while
current smokers in the whole cohort did present at a younger age
(63.4 years) compared to those who had never smoked (68.0) or
who were ex-smokers (69.5), this was not apparent in those with
NAFLD related HCC (current smokers 70.3; never smoked 68.0;
ex smokers 71.9). While the published literature clearly indicates
that smoking is an important risk factor for HCC, it was unlikely
to have been a key contributor to the increase observed in our
region. Moreover, it was not an obvious co-factor in our own
small series of patients with NAFLD related HCC.
Finally, Dr Braillon has also questioned NAFLD as an entity in
its own right, pointing out that liver disease per se can produce
insulin resistance and suggesting that obesity is not necessarily
an independent cause of chronic liver disease. We agree that
obesity and type 2 diabetes are likely contributors to progres-
sion of chronic liver disease irrespective of the primary underly-
ing cause. However, contrary to some early reports, there are
now a substantial number of large series presenting the evi-
dence for NAFLD and its risk of progression [5–7], as recently
reviewed [8]. In our own cohort, patients classed as having
NAFLD were men or women with evidence of a fatty liver on
biopsy or imaging, with an otherwise negative liver screen,
drinking <21 or 14 units of alcohol per week respectively for
at least 5 years prior to their ﬁrst presentation with liver
disease.
Letters to the EditorTo the Editor:
We thank Dr Braillon for drawing attention to our recent study
describing the increase in hepatocellular cancer (HCC) related
mortality in the decade following the introduction of the National
Health Service ‘Cancer Plan 2000’. Firstly, the reported increase in
mortality was based on factual data for our region, provided by
Public Health Englands’ North of England Cancer Networks
Knowledge and Intelligence team (Northern and Yorkshire)
(NYCRIS) (http://www.nycris.nhs.uk). This region is deﬁned by
the North East of England, Cumbria, and North Yorkshire and
has a stable population of approximately 3 million. Actual deaths
per annum attributed to HCC were 62 at the start of the decade,
vs. 111 at the end – an increase of 1.8-fold. Dr Braillon points out
this increase was higher than age-standardised incidence rates in
England, which we have suggested may reﬂect regional differ-
ences in the prevalence of obesity and type 2 diabetes [1].
We agree that improved means of HCC detection, as well as
advances in therapeutic options, should have an impact on mor-
tality. Earlier diagnosis is more likely for patients with known cir-
rhosis undergoing regular surveillance and certainly our study
conﬁrmed better outcomes for those individuals with HCC
detected at an earlier stage. The majority (>70%) however, pre-
sented with symptomatic disease, staged as C or D according to
the Barcelona Clinic for Liver Cancer (BCLC) system [2]. These
patients were unsuitable for ablative therapies. Sorafenib will
likely have an impact for those with BCLC – C disease (44.9% in
our cohort), but this medical treatment only became available
in England in 2010 [1]. Any impact was not apparent in the
cohort presenting between 2000 and 2010.
Dr Braillon has also raised the important issue of smoking and
HCC. While smoking prevalence is reportedly higher in the North
of England, it should also be recognised that it has fallen in all
regions, including the North, over the decade in which a rise in
HCC mortality has been documented [3]. However, these data
are of interest and were not reported in our cohort because we
did not wish to over interpret our relatively small series – a full
smoking history was not prospectively collected in every case
and an appropriate age and liver disease matched control popu-
lation for comparison was not available. Data was collected in
425/629 cases and we are pleased to have the opportunity toTable 1. The prevalence of smoking in patients with HCC in Northern England.
Etiology No CLD ALD NAFLD HCV HBV Haem Crypt AIH PBC Other Total 
HCC
Current smoker % 31 30 11 37 47 21 24 0 20 25 26
Ex-smoker % 37 32 46 29 21 46 47 57 53 0 37
Never smoked % 32 38 43 35 32 33 29 43 27 75 37
Data are presented as percentages.
CLD, chronic liver disease; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; HCV, hepatitis C virus; HBV, hepatitis B virus; Haem, haemochromatosis;
Crypt, cryptogenic cirrhosis; AIH, autoimmune hepatitis; PBC, primary biliary cirrhosis.
Cases in category ‘other’ included 3 with a-1-antitrypsin deﬁciency, 1 with primary sclerosing cholangitis, and 1 with congenital heart disease/cardiac cirrhosis.
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Response to locoregional treatment and alpha-fetoprotein trend in
liver transplant candidates for HCC: Dwarfs standing on the
shoulders of giants
To the Editor:
We read with great interest the correspondence on the paper
published by Otto et al., [1] on the response to repeated trans-
arterial chemo-embolization (TACE) as a discriminating tool for
selection of liver transplant (LT) candidates with hepatocellular
carcinoma (HCC). Paul et al. [2] evidenced the relative small sam-
ple size and the lack of information on the role of TACE on wait-
ing-list dropout. Our aim is to support the results obtained by
Otto et al. with the strength and the statistical power of a new
recently published European study.
Using prospectively recorded data from 6 Centers with
different allocation systems, we have conﬁrmed the role of the
response to locoregional treatments (LRT) as predictor of survival
and HCC recurrence [3]. mRECIST progression after LRT and
alpha-fetoprotein (AFP) slope >15 ng/ml/month resulted inde-
pendent predictors not only in 116 Milan-criteria (MC)-OUT,
but also in 306 MC-IN patients. Moreover, no TACE alone but also
different LRTs were performed in the routine pre-LT workout,
demonstrating that response to LRT works well independently
from the stage.
We agree on the Zurich Conference recommendations [4]: The
preoperative assessment of the size of largest tumor or total
diameter remains crucial. However, pre-operative radiological
staging for MC-IN and MC-OUT patients may differ in both direc-
tions in up to 25% of cases when compared to post-transplant his-
topathology [5]. Although response to LRTs has already been
shown in the beginning of the nineties as a useful tool for the
selection of HCC patients as the seminal paper by Majno et al.
clearly shows [6], the delayed introduction in clinical practice
of standardized and effective LRT techniques (TACE, radiofre-
quency ablation, radio-embolization) has hampered their routine
use in the pre-LT management of HCC. As a consequence, the
evaluation of the prognostic role of response after LRT has only
recently been implemented.
Mehta and Yao synthesized that there is ‘‘growing evidence
that size and number tell only a partial tale of the tumor charac-
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